What is it about?

Due to the rising antibiotic resistance, there is a dire need for development of novel antimicrobials. We report here a two-component lantibiotic termed as Roseocin, comprising of two synergistically acting peptides, for the first time from an Actinomycete instead of Firmicutes. It displays antimicrobial activity against important drug-resistant pathogens.

Featured Image

Why is it important?

New drugs are required for combating rising antimicrobial drug resistance. These novel peptides target the high priority pathogenic bacteria recognized by World Health Organization.


It was amazing to know that the two peptides are partners, they are generated by the bacteria from their respective genes, but don't work separately. When combined together they kill the target pathogenic bacteria.

Mangal Singh
Panjab University

Read the Original

This page is a summary of: Roseocin, a novel two‐component lantibiotic from an actinomycete, Molecular Microbiology, November 2019, Wiley, DOI: 10.1111/mmi.14419.
You can read the full text:




The following have contributed to this page